Abivax SA research snapshot
ABVX AI stock analysis currently reads Abivax SA as a late-stage biotechnology company whose value depends primarily on obefazimod, an oral miR-124 enhancer being developed for ulcerative colitis and Crohn's disease. The Phase 3 ABTECT maintenance results were positive, the company reported additional positive maintenance data on June 29, and management plans a U.S. NDA submission in late Q4 2026. Abivax also completed a $920 million public offering on July 6, with estimated net proceeds of about $874.1 million. At the July 12, 2026 data cutoff, ABVX closed at $139.90 on July 10, implying a calculated market capitalization of about $12.11 billion after the offering. This ABVX AI stock analysis uses conditional scenarios and source-backed facts for information only. It is not investment advice.
Current price
$139.90 at the July 10, 2026 Nasdaq close
Market cap
$12.11 billion calculated from 86.55 million shares; StockAnalysis reports about $12.08 billion
AI score
69 / 100
Rating
Late-stage biotech with strong Phase 3 ulcerative colitis data, major financing, and approval plus launch risk
Trend status
Long-term bullish after positive ABTECT data; short-term volatile after a large equity offering
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Abivax is a focused clinical-stage biotech built around obefazimod, a once-daily oral candidate for chronic inflammatory bowel disease. It has clinical proof but no approved product revenue. | High |
| Moat | The potential moat is the differentiated miR-124 mechanism, accumulated clinical data, patent estate, and regulatory know-how. Network effects, switching costs, and commercial scale are not yet proven. | Medium |
| Management | CEO Marc de Garidel has prior biotech transaction and pharmaceutical leadership experience. The next test is disciplined use of the new capital and execution of a U.S. launch if obefazimod is approved. | Medium |
| Financial trend | FY2025 revenue fell to €4.57 million while operating loss widened to €246.1 million and operating cash use reached €161.1 million. The July financing improves liquidity but also increases the share count. | High |
| Valuation | At about $12.1 billion of equity value, ABVX has no meaningful PE or FCF valuation because earnings and free cash flow are negative. The market price reflects substantial expected value from approval and future sales. | High |
| Technical trend | The July 10 close was above the calculated 20-session SMA of $114.35 and near the recent high zone, but the stock has shown very wide daily ranges and high event-driven volume. | Medium |
| Risk level | Risk is high because one lead asset drives most of the thesis, regulatory and safety outcomes remain ahead, commercial competition is strong, and the recent offering creates dilution and repricing risk. | High |
| AI confidence | Confidence is higher for historical facts and lower for any forecast that assumes approval, pricing, market share, or a specific launch timeline. | Medium-high data confidence |
| Investment certainty | The clinical thesis is credible but not yet a durable business thesis. Investment certainty depends on the FDA path, commercial positioning, and evidence that the balance sheet can fund launch without repeated dilution. | Low-medium |
ABVX AI stock forecast
The ABVX AI stock forecast is a conditional framework, not a price promise. The audited three-scenario EPS command is not decision-useful because FY2025 EPS was negative, so the ranges below are market-repricing bands tied to approval, commercialization, cash use, and clinical execution rather than fabricated intrinsic-value targets.
$200 to $300
More likely if the Q4 2026 NDA is accepted on schedule, FDA review remains supportive, obefazimod reaches approval, the U.S. launch earns strong prescriber and payer adoption, and Crohn's disease data adds a second growth option.
$100 to $180
More likely if the regulatory path advances but approval timing, pricing, launch spending, or market share remain uncertain. The new cash can fund the program, while the stock continues to trade on milestones rather than current earnings.
$45 to $95
More likely if the FDA requests additional work, safety or manufacturing issues appear, approval is delayed or denied, commercial uptake disappoints, Crohn's disease data weakens the platform story, or further financing becomes necessary.
ABVX AI technical analysis
ABVX AI technical analysis is constructive on the longer trend but highly volatile as of the July 10, 2026 close. Price was above a calculated 20-session SMA of $114.35, while recent sessions showed heavy volume around the financing and clinical-data repricing. The source snapshot did not provide a complete 50-day or 200-day series, so those values are not invented here.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $139.90 | StockAnalysis historical data, July 10, 2026 Nasdaq close. The close was below the $141.00 intraday high and above the $137.72 low. |
| Immediate support | $136.85 to $138.50 | Recent July lows from the July 8 to July 10 sessions. A close below this zone would weaken the immediate consolidation structure. |
| Financing reference | $125.00 | The July 2026 public offering price per ADS. It is a reference level for post-offering acceptance, not a guaranteed technical floor. |
| First resistance | $141.99 to $145.01 | Recent session highs from July 7 and July 9. A close above this zone with confirming volume would improve short-term momentum. |
| Higher resistance | $147.98 to $148.83 | The July 6 high and the reported 52-week high area. A decisive break would put the stock into price discovery. |
| Moving averages | 20-session SMA $114.35; 50-day and 200-day SMA not independently verified | The 20-session average is calculated from the last 20 completed daily closes available in the source snapshot through July 10, 2026. |
| Momentum | +44.9% from the June 12 close to July 10; -2.8% from the July 6 close | The mixed time-frame result shows strong medium-term momentum with a recent pause. No RSI value is used because it was not available in the current source snapshot. |
| Volume | 791,794 shares on July 10; 4.02 million on July 2; 8.95 million on June 30 | Volume expanded sharply around the financing and clinical milestones, confirming event risk and the need for smaller position sizing in any trading framework. |
| Volatility | 52-week range $7.77 to $148.83 | The broad range reflects the binary nature of clinical-stage biotech valuation and makes gap risk more important than a single indicator. |
| Invalidation | Close below $125, then deeper risk below $114.35 | A close below the offering reference would weaken the post-financing structure. A break below the calculated 20-session SMA would weaken the medium-term trend setup. |
ABVX AI trading strategy
The ABVX AI trading strategy is a non-personal framework for a milestone-driven biotechnology stock. Any use should include live quotes, position sizing, clinical and regulatory calendars, SEC filings, and explicit rules for event gaps. It is not investment advice.
Wait for a close above the $141.99 to $145.01 resistance zone, then look for a retest that holds with volume and no adverse regulatory or safety news. A later break above $148.83 would confirm a new high, but it would not remove approval risk.
Treat a close below $136.85 as a failed near-term breakout and a close below $125 as a deeper invalidation of the post-offering trend framework.
A pullback toward $125 to $138 can be monitored only after price stabilizes and the clinical thesis remains unchanged. Compare any bounce with volume, the offering price, new company filings, and the next regulatory milestone.
Do not treat a sharp decline as automatically oversold. A regulatory, safety, or manufacturing development can move through support without a technical bounce.
Track the Q4 2026 NDA submission, FDA acceptance and review milestones, ABTECT safety follow-up, ENHANCE-CD data expected in mid-2027, cash use, launch hiring, payer access, and any partnership or commercialization update.
Reduce confidence if the NDA slips, the FDA requests material additional work, safety interpretation changes, cash burn accelerates, or management issues new shares before reaching a commercial funding milestone.
Investment research summary
Abivax is trying to turn one differentiated oral anti-inflammatory mechanism into a commercial medicine. Obefazimod is designed to increase miR-124, a natural regulator of inflammatory pathways, and is being tested in ulcerative colitis and Crohn's disease. The company has clinical assets, not a recurring product business yet.
The current moat is prospective rather than commercial: a novel mechanism, an expanding clinical dataset, intellectual property, trial execution, and regulatory experience. There are no meaningful network effects or switching costs today, and competing IBD therapies can limit pricing and adoption even after approval.
The thesis can fail through a regulatory request, an unexpected safety signal, manufacturing delay, a weaker benefit-risk assessment, poor payer access, slow physician adoption, or an unsuccessful Crohn's program. The July offering reduces near-term liquidity risk but raises the share count and can create a higher valuation hurdle.
CEO Marc de Garidel has more than 40 years in pharma and biotechnology and previously led transactions involving Corvidia Therapeutics and CinCor Pharma. The July 2026 offering at $125 per ADS, with estimated net proceeds of $874.1 million, gives the team capital for potential U.S. commercialization and further trials. The record of post-approval execution remains untested at Abivax.
Inflammatory bowel disease has durable medical need and a large treatment market, while oral therapies can be attractive compared with injectable biologics. The market is also crowded, with established biologics, small molecules, payer negotiations, and changing treatment guidelines. A positive clinical result does not guarantee a durable commercial advantage.
At a calculated equity value of about $12.11 billion, ABVX traded at a very large multiple of FY2025 revenue because revenue was only €4.57 million and FY2025 EPS was negative. PE and FCF yield are not useful as positive valuation anchors. The margin of safety depends on approval probability, future sales, cash runway, and the price paid for those uncertain outcomes.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ABVX latest completed-session price | $139.90 at the July 10, 2026 Nasdaq close | StockAnalysis historical data | July 12, 2026 |
| Market capitalization | $12.11 billion calculated as $139.90 x 86.545 million shares; reported market cap about $12.08 billion; verification variance 0.23% | StockAnalysis and financial_rigor.py | July 12, 2026 |
| Shares reference after July 2026 offering | 79.185 million ordinary shares were reported as outstanding or beneficially outstanding in the 2025 20-F reference period; 7.36 million ADSs were issued in July 2026, implying about 86.545 million before other changes | Abivax 2025 Form 20-F and July 2026 offering release | July 12, 2026 |
| Five-year revenue trend | €11.96M in 2021, €4.58M in 2022, €4.62M in 2023, €12.45M in 2024, and €4.57M in 2025 | StockAnalysis financials and Abivax 2025 Form 20-F | July 12, 2026 |
| FY2025 operating loss and net loss | Operating loss €246.1M; net loss €336.1M; basic EPS -€4.83 | Abivax 2025 Form 20-F and FY2025 results release | July 12, 2026 |
| Operating cash use and free cash flow | Cash used in operating activities was €161.1M in 2025; StockAnalysis reports FY2025 free cash flow of -€161.27M | Abivax FY2025 results and StockAnalysis cash flow | July 12, 2026 |
| Cash and short-term investments | €530.4M at December 31, 2025; €491.6M at March 31, 2026 before the July offering. After the offering, Abivax said current resources are expected to fund operations into Q4 2029. | Abivax FY2025 release, Q1 2026 filing, and StockAnalysis balance sheet | July 12, 2026 |
| ABTECT Phase 3 maintenance result | At Week 44, clinical remission was 50.8% for 25 mg and 51.3% for 50 mg versus 10.4% for placebo; both primary comparisons had p<0.0001 in N=580 | Abivax ABTECT maintenance release | July 12, 2026 |
| ABTECT Maintenance Part 2 result | 37.2% of induction non-responders achieved clinical remission and 34.5% achieved endoscopic remission at Week 44 after continued 50 mg treatment | Abivax ABTECT Maintenance Part 2 release | July 12, 2026 |
| Regulatory and clinical milestones | Planned U.S. NDA submission for obefazimod in late Q4 2026; Crohn's disease Phase 2b induction topline results expected mid-2027 | Abivax investor relations and clinical program releases | July 12, 2026 |
| July 2026 public offering | 7.36 million ADSs at $125 each; gross proceeds about $920.0M and estimated net proceeds about $874.1M | Abivax offering closing release | July 12, 2026 |
| Technical snapshot | 20-session SMA calculated at $114.35; July 10 volume 791,794; 52-week range $7.77 to $148.83 | StockAnalysis historical data and financial_rigor.py calculations | July 12, 2026 |
| Management reference | Marc de Garidel is CEO; Abivax reports more than 40 years of pharma and biotechnology experience and prior leadership of Corvidia and CinCor transactions | Abivax management profile | July 12, 2026 |
This ABVX AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are conditional scenarios based on available data as of July 12, 2026 and can be wrong if clinical results, regulation, competition, financing, launch execution, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
